Welcome to our dedicated page for UNITED THERAPEUTICS SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics (UTHR) insider activity: Martine A. Rothblatt, Chairperson & CEO, exercised 8,000 stock options at an exercise price of $120.26 on 09/09/2025 and sold two blocks of common stock totaling 8,000 shares (6,165 shares at a weighted average price of $398.285 and 1,835 shares at a weighted average price of $399.4263). The transactions were executed pursuant to a pre-arranged 10b5-1 trading plan established May 2, 2025, covering a tranche of 294,000 stock options that expire March 15, 2026 and continuing until exhaustion of that tranche or December 31, 2025. The Form 4 reports direct and indirect holdings via spouse and family trusts as disclosed.
United Therapeutics Corp (UTHR) director Tommy G. Thompson reported option exercise and simultaneous sale transactions on 09/10/2025. He exercised a stock option at an exercise price of $229.81 to acquire 4,560 shares and immediately sold 4,560 shares at $403.36. After these reported transactions the filing shows the reporting person beneficially owned 8,480 shares directly plus 8,200 shares held indirectly by a trust and 5,800 shares held indirectly by a family LLC. The filing notes 880 shares to be issued on or about July 8, 2026 from a deferred RSU election tied to a July 7, 2023 vesting.
United Therapeutics (UTHR) filed a Form 144 reporting a proposed sale of 4,560 common shares via Morgan Stanley Smith Barney on NASDAQ. The filing states the shares were acquired and are to be sold on 09/10/2025 through a stock option exercise and were paid for in cash on that date. The aggregate market value of the shares to be sold is listed as $1,839,321.60 against 45,226,262 shares outstanding, indicating the sale represents a small fraction of total shares. The filer certifies they know of no undisclosed material adverse information.
United Therapeutics (UTHR) filed a Form 144 reporting a proposed sale of 8,000 common shares. The shares are to be sold through TD Securities (USA) LLC on NASDAQ with an approximate sale date of 09/09/2025 and an aggregate market value reported as $3,188,374.33. The filing shows the shares were originally acquired on 03/15/2016 under an executive deferred compensation arrangement from Martine Rothblatt. The method of payment is described as shares exercised via a vested option and payment via common shares. The filer reports no securities sold in the past three months and provides the required representation about absence of undisclosed material adverse information.
United Therapeutics Corp (UTHR) filed a Form 144 disclosing a proposed sale of 700 shares of common stock through Morgan Stanley Smith Barney LLC, scheduled approximately on 09/09/2025. The filing lists an aggregate market value of $280,203.00 for the shares and shows 45,226,262 shares outstanding. The securities were acquired as restricted stock from the issuer in two grants dated 06/26/2025 (110 shares) and 07/25/2025 (590 shares). The notice includes the standard attestation that the seller is not aware of undisclosed material adverse information and that intentional misstatements are a federal offense.
United Therapeutics (UTHR) Form 144: This notice reports a proposed sale of 11,000 common shares through Morgan Stanley Smith Barney on 09/04/2025 with an aggregate market value of $4,237,280.30. The filing shows the shares were acquired the same day by stock option exercise and paid in cash. The issuer's total shares outstanding are listed as 45,226,262, and the filer previously sold six identical blocks of 11,000 shares each between 06/12/2025 and 08/21/2025, generating gross proceeds ranging from about $3.08M to $3.40M per sale. The form includes the seller's representation that no undisclosed material information is known.
United Therapeutics insider Michael Benkowitz executed option exercises and sold shares under a Rule 10b5-1 plan. On 09/02/2025 Mr. Benkowitz exercised stock options with strike prices of $135.42 and $146.03, resulting in 22,500 option-related shares reported as acquired across two option series. He then sold multiple tranches of common stock on 09/01–09/02/2025 at prices ranging from $405.54 to $419.63, with weighted-average prices reported for each tranche. The shares are held in trusts for which the reporting person has either shared or sole investment and voting power. The filing was signed under power of attorney on 09/04/2025.
Christopher Causey, a director of United Therapeutics Corporation (UTHR), reported exercising 3,000 stock options and immediately selling the resulting shares on 09/02/2025 under a pre-arranged 10b5-1 plan entered on 12/24/2024. The option exercise had an exercise price of $132.30 per share for options granted 06/28/2018 that expire 06/28/2027. The filing shows three sales of 1,000 shares each at $419.63, $430.00, and $420.00. Following these transactions, Causey’s beneficial ownership of common stock declined from 7,865 shares to 4,865 shares. The Form 4 was executed under power of attorney and the transactions are recorded as being made pursuant to the specified 10b5-1 plan.
United Therapeutics insider filed a Form 144 to sell 112,500 shares of common stock on 09/02/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The filing lists an aggregate market value of $34,285,500.00 and reports 45,226,262 shares outstanding. The shares were acquired the same day, 09/02/2025, by exercise of stock options and paid in cash. No securities were reported sold by the person in the prior three months, and the filer represents they have no undisclosed material adverse information.
United Therapeutics Corp (UTHR) filing a Form 144 notifies a proposed sale of 3,000 common shares on 09/02/2025 through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $1,269,630.00. The shares were acquired the same day by stock option exercise and paid in cash. The filer reports no securities sold in the past three months and affirms they are unaware of undisclosed material adverse information. The notice includes standard Rule 144 and 10b5-1 representations.